3 New Strong Buy Ratings from Top-Rated Analysts: 02/04/2025
Each week, WallStreetZen publishes dozens of Strong Buy ratings from top-rated analysts. It’s a premium feature on our site, but we’ve unlocked a FREE sampling for you today. Here’s what we’ve got today:
- Amneal Pharmaceuticals Inc (NASDAQ: AMRX) doesn’t have the name recognition factor of stocks like Eli Lilly or Moderna, but it DOES have impressive growth potential — discover this under-the-radar pick before the masses.
- Diversified medical play Stryker Corp (NYSE: SYK) finished 2024 strong, and analysts believe the momentum could continue.
- Despite tariff fears, Royal Caribbean Cruises Ltd (NYSE: RCL) remains a Strong Buy in analysts’ eyes. Could the recent drop be an opportunity to buy the dip?
Gain access to dozens of alerts like this per week 👉👉 Try WallStreetZen Premium
1- Stryker Corp (NYSE: SYK)
This diversified medical play wears a lot of hats — whether you need advanced surgical equipment, a joint implant, or even a full-blown robotic-assisted surgery system, Stryker Corp can provide it. On January 28, the company held its Q4 and full-year 2024 earnings report — and some of Wall Street’s best think that such a strong finish to the year is just a taste of what’s to come.
Zen Rating: B (Buy) — see full analysis >
Recent Price: $391.29 — get current quote >
Max 1-year forecast: $450.00
Why we’re watching:
- A whopping 16 analysts track SYK stock. A little over one-half — 9, to be exact, gave it a Strong Buy rating. The remaining 7 ratings are split, 5 to 2, between Buy and Hold ratings. See the ratings
- Stifel Nicolaus equity researcher Rick Wise (a top 6% rated analyst) maintained a prior Strong Buy rating on January 29.
- Wise set a $440 price target for Stryker Corp, reflecting on the fact that the company beat estimates across several key metrics. In addition, Wise opined that several changes are ongoing in the healthcare sector which appear to augur well for 2025.
- SYK’s Zen Rating of B puts it in the top 20% of all stocks that are tracked by our proprietary quant system.
- The company’s strong balance sheet nets it a Financial Component Grade rating of B — while its 2-year-long uptrend has secured it a B rating when it comes to the Safety Component Grade rating.
- In addition, our Artificial Intelligence (AI) Component Grade rating of B hints at the fact that subtle market data suggests that SYK is primed for outperformance. (See all 7 Zen Component Grades here >)
2- Amneal Pharmaceuticals Inc (NASDAQ: AMRX).
It might not have the name recognition that some larger pharma companies do, but this mid-cap stock has provided an impressive yearly return. Analysts are almost unanimously bullish on Amneal Pharmaceuticals — and with a strong product pipeline and promising developments in terms of drug approval, this business seems to be gearing up for a strong showing in 2025.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $8.26 — get current quote >
Max 1-year forecast: $12.00
Why we’re watching:
- Analyst support: Of the 4 stock analysts who track AMRX and issue ratings for it, 3 deem it a Strong Buy, and only 1 rates it a Hold. See the ratings
- Notably, David Amsellem (a top 14% rated analyst) of Piper Sandler, recently increased his price target for AMRX stock to $11 from $9.
- Ansellem maintained a prior Strong Buy rating, emboldened by the company’s 25% earnings per share (EPS) beat last quarter. Amneal also beat revenues last time around — and the business will hold its next earnings call on February 28.
- In addition, the Food and Drugs Administration (FDA) recently accepted a new drug application (NDA) from the company for IPX203 — a novel treatment for Parkinson’s disease, as well as an extended-release version of its Alzheimer’s disease treatment, Memantine.
- AMRX stock carries a Zen Rating of A. Since the early 2000s, stocks that carry this distinction have provided an average annual return of 32.52%.
- In terms of Component Grade scores, Amneal Pharmaceuticals has two particularly bright spots — its Sentiment rating and Value rating. In the former, ARMX stock is ranked in the 97th percentile, suggesting it’s a “Smart Money” favorite, and in the latter, it ranks in the top 7% of all the stocks we track. (See all 7 Zen Component Grades here >)
3- Royal Caribbean Cruises Ltd (NYSE: RCL)
A Royal Caribbean Cruise sure sounds relaxing — but in case you’re constrained by your checkbook, consider that investing in RCL stock a year ago would have netted you a 118.40% return. Although it is currently trading at an all-time high, a pullback doesn’t seem likely, as the business recently released a standout quarterly report.
Zen Rating: B (Buy) — see full analysis >
Recent Price: $269.09 — get current quote >
Max 1-year forecast: $310.00
Why we’re watching:
- At present, RCL stock is a strong consensus Strong Buy. In total, 16 analysts track the stock — 10 deem it a Strong Buy, 4 rated it a Buy, and only 2 have given it a Hold rating. See the ratings
- Christopher Stathoulopoulos, a Susquehanna researcher (a top 3% rated analyst), maintained a prior Strong Buy rating, but increased his price target from $245 to $305 on January 29.
- The analyst noted that the company's debut in the river cruise market through its premium brand, Celebrity Cruises, for which bookings are being accepted this year, gives Royal Caribbean Cruises access to a rapidly expanding market.
- In a similar vein, John Staszak of Argus Research (a top 12% rated analyst) opined that Wave Season (Christmas through March) is off to a great start, which bodes well for ongoing high demand and could lead to better-than-expected profits and revenue.
- RCL stock carries a Zen Rating of B — historically, this distinction has equated to an average annual return of 19.88%.
- In terms of Component Grade scores, Momentum is Royal Caribbean’s strong suit — as the stock is ranked in the top 5% according to this factor. (See all 7 Zen Component Grades here >)
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.